NHS England to remove financial incentives for structured medication reviews in 2023/2024

Incentives to switch patients to environmentally friendly inhalers and to prescribe more patients with edoxaban will also be scrapped.
Middle aged man in a medicines review with GP pharmacist
NHS England has said that £246m of the Impact and Investment Fund funding for 2023/2024 will now be diverted to “improving patient experience of contacting their practice"

Angela Hampton Picture Library / Alamy Stock Photo

Financial incentives for primary care networks (PCN) to carry out structured medication reviews (SMRs) are to be scrapped, following NHS England’s changes to the GP contract for 2023/2024.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated